Current and Emerging Therapeutics in Cystic Fibrosis: Ensuring Continuity of Care within the New Treatment Paradigm
This Continuing Education activity is supported by an educational grant from Vertex Pharmaceuticals, Inc.
This activity is supported by an educational grant from Vertex Pharmaceuticals, Inc.
Robert J. Kuhn, BS, PharmD
Kentucky Hospital Association Endowed Professor
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Elizabeth Autry, PharmD
Pediatric Clinical Pharmacist
Pediatric Pulmonary and Endocrinology
Specialty Pharmacy Services
University of Kentucky HealthCare
After completing this continuing education program, the participant will be able to:
- Apply knowledge of the changing face of cystic fibrosis (CF), in terms of microbiology and patient demographics, to optimize treatment efficacy, treatment adherence, and overall management of CF
- Illustrate the pathobiology and pathogenesis of CF and the role of existing therapeutics
- Examine the importance of airway clearance and the continued role of chronic suppressive antibiotic therapy in treatment of pulmonary exacerbations
- Analyze the latest clinical data on agents targeting various mutations in CF
- Explore the potential impact of clinical advances in CF on multimodal treatment options and strategies, and communicate effectively with patients and their families about the role of genetic analyses
care, and community retail pharmacists
Type of activity: Application
Release date: December 7, 2015
Expiration date: December 7, 2016
Estimated time to complete activity: 2.0 hours
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-15-154-H01-P. The activity is available for CE credit through December 7, 2016.